What are bendroflumethiazide, hydrochlorothiazide, and chlorthalidone, to which drug class do they belong, and why are they used in the management of hypertension?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 19, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Thiazide and Thiazide-Like Diuretics for Hypertension

Bendroflumethiazide, hydrochlorothiazide, and chlorthalidone are thiazide-type diuretics—a class of first-line antihypertensive medications that lower blood pressure by promoting sodium and water excretion through the kidneys, reducing blood volume and vascular resistance.

Drug Classification and Mechanism

These three medications belong to the thiazide-type diuretic class, though they differ slightly in chemical structure 1, 2, 3:

  • Bendroflumethiazide and hydrochlorothiazide (HCTZ): True thiazides containing a benzothiadiazine ring 4
  • Chlorthalidone: Technically a "thiazide-like" diuretic lacking this ring structure but functioning similarly 5

All three work by inhibiting the sodium-chloride cotransporter in the distal convoluted tubule of the kidney, promoting natriuresis (sodium excretion) and subsequent water loss, which reduces intravascular volume and ultimately lowers blood pressure 6, 7.

Why They're Used for Hypertension Management

Proven Cardiovascular Benefits

Thiazide-type diuretics are recommended as first-line therapy because high-quality randomized controlled trials have demonstrated they prevent cardiovascular disease events including myocardial infarction, stroke, heart failure, and cardiovascular death 2. The evidence base is particularly strong—these medications have been tested in landmark trials showing mortality and morbidity reduction 6, 8.

Guideline-Recommended First-Line Agents

Current guidelines position thiazide-type diuretics alongside three other drug classes (ACE inhibitors, ARBs, and calcium channel blockers) as preferred initial therapy 2, 7:

  • For patients >55 years old: Thiazide-type diuretics are recommended when calcium channel blockers are unsuitable or when heart failure risk is present 1
  • For Black patients of any age: Thiazide-type diuretics serve as alternatives to calcium channel blockers 1
  • For combination therapy: Thiazide-type diuretics combine effectively with ACE inhibitors, ARBs, or calcium channel blockers in Step 2 and Step 3 treatment algorithms 1

Important Distinctions Between Specific Agents

When initiating or changing diuretic therapy, chlorthalidone (12.5-25 mg daily) or indapamide should be preferred over conventional thiazides like bendroflumethiazide or hydrochlorothiazide 1. This recommendation stems from:

  • Superior 24-hour blood pressure control: Chlorthalidone provides greater systolic BP reduction (approximately 5 mmHg more) and diastolic BP reduction (approximately 3 mmHg more) compared to HCTZ, with particularly better nocturnal control 9, 10, 11
  • Longer half-life: Chlorthalidone's extended duration of action (40-60 hours vs. 6-12 hours for HCTZ) provides more consistent BP lowering 12, 9
  • Stronger trial evidence: Most major cardiovascular outcome trials (ALLHAT, SHEP) used chlorthalidone, not HCTZ 6, 13, 12

Critical Caveat on Switching

However, if patients are already stable and well-controlled on bendroflumethiazide or hydrochlorothiazide, continue their current therapy rather than switching 1. A large pragmatic trial found no significant cardiovascular benefit when switching from HCTZ to chlorthalidone in stable patients 2.

Practical Dosing Considerations

Effective doses used in successful morbidity trials 6:

  • Hydrochlorothiazide: 25-50 mg once daily
  • Chlorthalidone: 12.5-25 mg once daily
  • Bendroflumethiazide: 5 mg once daily (in combination products) 4

Higher doses add minimal antihypertensive benefit but increase adverse effects, particularly hypokalemia 6.

Safety Profile and Monitoring

Common Side Effects

  • Electrolyte abnormalities: Hypokalemia (more common with chlorthalidone), hyponatremia 6, 13, 10, 14
  • Metabolic effects: Hyperuricemia (rarely causing gout at recommended doses), mild glucose elevation, potential new-onset diabetes 6, 8
  • Renal effects: Chlorthalidone carries higher risk of acute kidney injury and chronic kidney disease compared to HCTZ 14, 15

Monitoring Requirements

Check serum sodium, potassium, and renal function within 2-4 weeks after initiation or dose escalation 1, 13, 1. This is particularly important with chlorthalidone given its higher risk of electrolyte disturbances 10, 14, 15.

Comparative Safety

Recent large-scale observational studies reveal chlorthalidone causes significantly more hypokalemia (HR 2.72), hyponatremia (HR 1.31), and acute renal failure (HR 1.37) compared to HCTZ 14, 15. Despite superior BP lowering, these safety concerns must be weighed against potential cardiovascular benefits.

Special Populations

Advanced Chronic Kidney Disease

Thiazide-type diuretics, particularly chlorthalidone, remain effective even with eGFR <30 mL/min/1.73 m² 13. Don't automatically discontinue when kidney function declines—one study showed chlorthalidone 25 mg reduced 24-hour ambulatory BP by 10.5 mmHg in patients with mean eGFR of 27 mL/min/1.73 m² 13. However, loop diuretics may be needed for volume control at very low GFR.

Resistant Hypertension

In Step 4 treatment for resistant hypertension, increasing thiazide-like diuretic doses is appropriate when serum potassium >4.5 mmol/L 1. Volume expansion frequently underlies treatment resistance, making adequate diuresis essential 9.

Bottom Line Algorithm

For new diuretic prescriptions in hypertension:

  1. Choose chlorthalidone 12.5-25 mg daily over HCTZ or bendroflumethiazide for superior BP control 1, 2, 1, 7
  2. Monitor electrolytes and renal function within 2-4 weeks 1, 13
  3. Accept higher hypokalemia risk with chlorthalidone; supplement potassium or use potassium-sparing agents if needed 10, 14

For patients already stable on HCTZ or bendroflumethiazide:

  1. Continue current therapy—don't switch 1, 2, 1, 2
  2. Maintain routine monitoring

In advanced CKD (eGFR <30):

  1. Consider chlorthalidone over HCTZ for better efficacy 13
  2. Monitor electrolytes more frequently
  3. Add loop diuretic if volume control inadequate 13

References

Guideline

blood pressure and the new acc/aha hypertension guidelines.

Trends in Cardiovascular Medicine, 2020

Guideline

kdoqi us commentary on the 2017 acc/aha hypertension guideline.

American Journal of Kidney Diseases, 2019

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.